Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 573 | 70 | 492 |
| Samples | 284 | 50 | 228 |
| Peptides | 216 | 33 | 186 |
Function
FBXL4 · F-box and leucine rich repeat protein 4
This gene encodes a member of the F-box protein family, which are characterized by an approximately 40 amino acid motif, the F-box. F-box proteins constitute one subunit of modular E3 ubiquitin ligase complexes, called SCF complexes, which function in phosphorylation-dependent ubiquitination. The F-box domain mediates protein-protein interactions and binds directly to S-phase kinase-associated protein 1. In addition to an F-box domain, the encoded protein contains at least 9 tandem leucine-rich repeats. The ubiquitin ligase complex containing the encoded protein may function in cell-cycle control by regulating levels of lysine-specific demethylase 4A. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 216 amino-acid changes on canonical ENST00000369244 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FBXL4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FBXL4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 7/42 17% | 23/612 4% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Biliary Tract Carcinoma | 0/54 0% | 14/950 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 9/810 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Colorectal Carcinoma | 8/143 6% | 29/3239 1% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 16/1390 1% |
| Gastric Carcinoma | 1/74 1% | 19/1809 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Other Solid Cancers | 0/94 0% | 14/1515 1% |
| Hepatocellular Carcinoma | 1/46 2% | 17/2210 1% |
| Melanoma | 2/210 1% | 13/1899 1% |
| Other Sarcomas | 0/69 0% | 5/699 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 11/2550 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 8/2534 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
Mutation Distribution
Where FBXL4 is mutated · all tissues, split by cell line vs tissue
How many mutations in FBXL4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 573 mutations in FBXL4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|